Compare Bank of America Corp (BAC) vs Incyte Corporation (INCY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bank of America Corp vs Incyte Corporation — how do they compare? Bank of America Corp trades at $61.59 (market cap $425.43B), while Incyte Corporation trades at $115.02 (market cap $22.95B). The key difference: Bank of America Corp is far larger — about 18.5× Incyte Corporation's market cap, and Bank of America Corp pays a 1.85% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| BAC | INCY | |
|---|---|---|
Market Cap | $425.43B | $22.95B |
Volume | 55,637,172 | — |
Sector | Financials | Health |
52-Week High | $60.62 | $118.52 |
52-Week Low | $44.92 | $67.38 |
Dividend Yield | 1.85% | — |
Enterprise Value | — | $18.97B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bank of America (BAC) trades at $59.50, down 0.28% today, with a bullish technical outlook and strong fundamental support. The stock shows consistent earnings beats, with Q2 2026 EPS of $1.21 exceeding the $1.13 estimate. Revenue growth accelerated to $113.1 billion in 2025, and the P/E ratio of 14 remains attractive. Recent news highlights strategic partnerships and hiring initiatives, reinforcing long-term growth prospects.
BAC presents a favorable investment case with solid profitability, a 64.8% analyst buy rating, and a consensus price target of $63.79 offering 7.2% upside. Risks include sensitivity to interest rates and macroeconomic volatility, but the bank's deposit franchise and capital flexibility provide resilience. The stock is well-positioned for steady appreciation amid supportive technicals and fundamental strength.
Incyte (INCY) trades at $114.23, down 2.12% today, with a bullish technical signal supported by moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $1.81, and revenue growth continues with 2025 revenue at $5.14 billion. Recent developments include positive Phase 1/2 data for VGA039 and the acquisition of Vega Therapeutics, expanding its hematology portfolio.
Outlook remains positive with analyst consensus favoring a Buy rating and a $112.78 price target. Key opportunities include pipeline advancements and robust profitability margins, while risks involve regulatory hurdles and competitive pressures in the biopharmaceutical sector. Earnings growth and product approvals are critical catalysts for future performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bank of America Corp
Bank of America Corporation operates as a financial holding company. The Company offers saving accounts, deposits, mortgage and construction loans, cash and wealth management, certificates of deposit, investment funds, credit and debit cards, insurance, mobile, and online banking services. Bank of America serves customers worldwide.
Read more on BAC →About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →
